Former CEO of California Stem Cell Agency Named to Board of Firm that Received $19 Million From the Agency
By David Jensen,
California Stem Cell Report
| 07. 07. 2014
Untitled Document
Alan Trounson, the former president of the $3 billion California stem cell agency, today was named to the board of a company that has
received $19.4 million from the agency, raising fresh and serious questions about conflicts of interest at the state-funded research program.
Announcement of the appointment came only seven days after Trounson left state employment. Trounson has been dogged for some time with questions about his relationship to the company,
StemCells, Inc., of Newark, Ca., and its co-founder, eminent
Stanford researcher
Irv Weissman, who sits on the company’s six-man board and is chairman of its scientific advisory board.
StemCells, Inc., announced Trounson’s appointment in
a press release this morning. The publicly traded firm said it was “thrilled” to have Trounson on its board. The first sentence of its press release noted that he had served as head of “the largest scientific funding body for stem cell research in the world.”
Weissman is director of the
Institute of Stem Cell Biology and Regenerative Medicine at Stanford. He has
received $34.7 million from the agency...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
